



QR Pharma Presents at the University of Pennsylvania: Convergence of Factors Leading to Neurodegenerative Disorders

Berwyn, PA, September 20, 2012: [QR Pharma, Inc.](#) (QR), a clinical stage specialty pharmaceutical company committed to developing therapeutics with novel approaches for the treatment of Alzheimer's disease (AD), Parkinson's disease (PD) and other neurodegenerative disorders presented at the University of Pennsylvania in [Rod and Maryellen Eckenhoff's](#) Anesthesia department. Dr. Maccicchini discussed the most recent developments and the scientific community's better understanding of the causes of neurodegenerative disorders and how QR's technology coincides with this new knowledge.

Posiphen has been shown to reduce the levels of toxic proteins, such as APP/A β , tau/ptau and alpha-synuclein (aSyn), in the brains of patients with neurodegenerative disorders back to the levels found in normal healthy volunteers. Recent research has found that a number of neurodegenerative disease states, although distinct in nature, have very similar characteristics. While Alzheimer's disease was believed to be the consequence of an accumulation of A β (plaques) and p-tau (tangles), it is now understood that additional toxic proteins are elevated, such as aSyn. It is also understood that a number of neurodegenerative diseases, including PD, Down syndrome, traumatic brain injury and post-operative cognitive dysfunction, all have increased levels of A β , tau and aSyn. Since Posiphen has been shown to normalize levels of these toxic proteins in mildly cognitive impaired patients, it is an excellent candidate for development in these neurodegenerative disease states.

About [Posiphen®](#): QR's lead compound, Posiphen, is a small orally active compound with high blood brain barrier permeability. Posiphen reduces the levels of toxic proteins in the brains of patients with neurodegenerative disorders back to the levels found in normal healthy volunteers. By normalizing brain levels of alpha synuclein, beta amyloid and tau, it provides an avenue to treat a number of neurodegenerative disorders and attack the disease at the onset. We expect Posiphen to influence the disease early so as to prevent the onset or diminish the severity of cognitive decline. Since neurotoxic proteins cause inflammation in the brain, lowering their levels reduces inflammatory factors and lowers inflammation.

About QR Pharma, Inc: Headquartered in Berwyn, Pennsylvania, QR Pharma, Inc. is a clinical-stage specialty pharmaceutical company committed to developing therapeutics with novel approaches for the treatment of cognitive impairment in neurological disorders. QR currently has three product development programs - Posiphen for early stage Alzheimer's and Parkinson's disease, and BNC for advanced Alzheimer's disease. For more information on QR Pharma, please visit the company's website, www.qrpharma.com.

Contact: Maria L. Maccicchini, CEO
Tel: 610 727 3710
maccicchini@qrpharma.com
www.qrpharma.com